High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

Selective protein kinase inhibitors have only been developed against a small number of kinase targets. Here we demonstrate that "high-throughput kinase profiling" is an efficient method for the discovery of lead compounds for established as well as unexplored kinase targets. We screened a library of 118 compounds constituting two distinct scaffolds (furan-thiazolidinediones and pyrimido-diazepines) against a panel of 353 kinases. A distinct kinase selectivity profile was observed for each scaffold. Selective inhibitors were identified with submicromolar cellular activity against PIM1, ERK5, ACK1, MPS1, PLK1-3, and Aurora A,B kinases. In addition, we identified potent inhibitors for so far unexplored kinases such as DRAK1, HIPK2, and DCAMKL1 that await further evaluation. This inhibitor-centric approach permits comprehensive assessment of a scaffold of interest and represents an efficient and general strategy for identifying new selective kinase inhibitors.

[1]  C. Rommel,et al.  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. , 2006, Journal of medicinal chemistry.

[2]  G. G. Dubinina,et al.  In silico design of protein kinase inhibitors: successes and failures. , 2007, Anti-cancer agents in medicinal chemistry.

[3]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[4]  Stephen R. Johnson,et al.  Trends in kinase selectivity: insights for target class-focused library screening. , 2011, Journal of medicinal chemistry.

[5]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[6]  Gavin Harper,et al.  Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[7]  C. Croce,et al.  Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. , 2009, DNA and cell biology.

[8]  S. Soddu,et al.  HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage , 2009, Cell proliferation.

[9]  Xiaolin Hao,et al.  Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[10]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[11]  Holger Wesche,et al.  High throughput screening for protein kinase inhibitors. , 2005, Combinatorial chemistry & high throughput screening.

[12]  Daniel K Treiber,et al.  Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. , 2010, Chemistry & biology.

[13]  A. Cheng,et al.  Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR. , 2007, Bioorganic & medicinal chemistry letters.

[14]  C. Schiffer,et al.  BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. , 2007, The New England journal of medicine.

[15]  J. Jongstra,et al.  PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation , 2010, Molecular Cancer Therapeutics.

[16]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[17]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[18]  P. Zarrinkar,et al.  High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.

[19]  P. Cohen.  Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. , 2009, The Biochemical journal.

[20]  S. Knapp,et al.  New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  S. Powers,et al.  Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Meijer,et al.  Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase. , 2010, Bioorganic & medicinal chemistry letters.

[23]  P. Mak,et al.  Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the Cdc42-associated Tyrosine Kinase ACK1* , 2004, Journal of Biological Chemistry.

[24]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[25]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[26]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[27]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[28]  M. Kashem,et al.  Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. , 2008, Biochemical and biophysical research communications.

[29]  A. Kraft,et al.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. , 2009, Journal of medicinal chemistry.

[30]  L. Meijer,et al.  Synthesis and target identification of hymenialdisine analogs. , 2004, Chemistry & biology.

[31]  J. Yates,et al.  Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. , 2010, Cancer cell.

[32]  Sherry L. Niessen,et al.  Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening , 2010, Proceedings of the National Academy of Sciences.

[33]  D. Givol,et al.  Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells , 2010, Oncogene.

[34]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[35]  M. Schmitz,et al.  HIPK2, a Versatile Switchboard Regulating the Transcription Machinery and Cell Death , 2007, Cell cycle.

[36]  J. Mohler,et al.  Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.

[37]  B Li,et al.  Creating chemical diversity to target protein kinases. , 2004, Combinatorial chemistry & high throughput screening.

[38]  Andrew W. Murray,et al.  A Small-Molecule Inhibitor of Mps1 Blocks the Spindle-Checkpoint Response to a Lack of Tension on Mitotic Chromosomes , 2005, Current Biology.

[39]  Stefan Knapp,et al.  Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration , 2009, The Journal of experimental medicine.

[40]  E. Salmon,et al.  The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.

[41]  Peter G Schultz,et al.  A combinatorial scaffold approach toward kinase-directed heterocycle libraries. , 2002, Journal of the American Chemical Society.

[42]  P. Cohen,et al.  BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. , 2007, The Biochemical journal.

[43]  L Meijer,et al.  Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. , 2000, Chemistry & biology.

[44]  V. Stoll,et al.  Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. , 2009, Journal of medicinal chemistry.

[45]  S. Soddu,et al.  HIPK2: a multitalented partner for transcription factors in DNA damage response and development. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[46]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[47]  P. Cohen,et al.  Synthesis, Pim kinase inhibitory potencies and in vitro antiproliferative activities of diversely substituted pyrrolo[2,3-a]carbazoles. , 2010, Bioorganic & Medicinal Chemistry.

[48]  Marc Schmidt,et al.  Ablation of the spindle assembly checkpoint by a compound targeting Mps1 , 2005, EMBO reports.

[49]  U. McDermott,et al.  Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 , 2011, ACS medicinal chemistry letters.

[50]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[51]  M. Drysdale,et al.  Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. , 2007, Bioorganic & medicinal chemistry letters.

[52]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[53]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[54]  Gerhard Müller,et al.  The 'retro-design' concept for novel kinase inhibitors. , 2010, IDrugs : the investigational drugs journal.

[55]  Taebo Sim,et al.  Small Molecule Kinase Inhibitors Provide Insight into Mps1 Cell Cycle Function , 2010, Nature chemical biology.